At a glance
ClinicalIndex Comparison RecordN/ACompleted· 107 enrolled
Drug / intervention
ABT NG DES 48 EECSSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent System (EECSS) in Treatment of de Novo Native Coronary Artery Disease
In Brief
A clinical study evaluating ABT NG DES 48 EECSS for Coronary Artery Disease. Completed, enrolled 107 participants across 25 sites in 3 countries.
Detailed Summary
The purpose of this SPIRIT 48 study is to evaluate the safety and effectiveness of the ABT NG DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease (CAD) due to de novo native coronary artery long lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesAustralia, Taiwan, United States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJun 2020
Primary CompletionOct 2022
Study CompletionSep 2023
TodayJul 2026
First PostedFeb 24, 2020
Enrollment StartJun 17, 2020
Primary CompletionOct 5, 2022
Study CompletionSep 17, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.4 years ago
Interventions
ABT NG DES 48 EECSSdevice
Each participant will receive ABT NG DES 48 EECSS with appropriate diameter